

Curriculum Vitae

DeAnna J. Friedman-Klabanoff, MD, MS, FAAP, CTropMed®
Assistant Professor, Department of Pediatrics
Division of Infectious Diseases and Tropical Pediatrics
Center for Vaccine Development and Global Health
University of Maryland School of Medicine

Date: October 21, 2025

Contact Information

Business Address:	Department of Pediatrics Division of Infections Disease & Tropical Pediatrics Center for Vaccine Development and Global Health 685 W. Baltimore Street, Rm 480 Baltimore, Maryland 21201
Business Phone Number:	(410) 706-8695
Fax:	(410) 706-6205
E-Mail:	dfriedman@som.umaryland.edu
Foreign Languages:	French (basic)

Education

2001 – 2004	B.S., Medical Microbiology and Immunology, University of Wisconsin-Madison (Graduated with Distinction)
2005 – 2009	M.D., University of Wisconsin School of Medicine and Public Health
2017 – 2023	M.S., Epidemiology and Clinical Research, University of Maryland, Baltimore

Post Graduate Education and Training

2009 – 2012	Residency, Pediatrics, University of Minnesota Medical School
2016 – 2019	Fellowship, Pediatric Infectious Disease, University of Maryland School of Medicine

Certifications

2012	Pediatrics, American Board of Pediatrics, Active
2012	Certificate of Knowledge in Clinical Tropical Medicine and Traveler's Health (CTropMed®), American Society of Tropical Medicine and Hygiene
2019	Pediatric Infectious Diseases, American Board of Pediatrics, Active

Medical Licensures

2011 – 2016	Inactive, Minnesota
-------------	---------------------

2015 – 2019 Inactive, Wisconsin
2019 – present Active, Maryland

Employment History

Academic Appointments

2012 – 2014 Assistant Professor, Pediatrics, University of Minnesota Medical School
2014 – 2015 Clinical Instructor, Pediatrics, Duke University Human Resources for Health Program
2015 – 2016 Assistant Professor, Pediatrics, Medical College of Wisconsin
2016 – 2017 Clinical Fellow, University of Maryland Medical Center, Pediatric Infectious Diseases and Tropical Pediatrics, Baltimore, MD
2017 – 2020 Postdoctoral Fellow, University of Maryland School of Medicine, Department of Pediatrics, Division of Infectious Diseases and Tropical Pediatrics, Baltimore, MD
2020 – 2022 Instructor, University of Maryland School of Medicine, Department of Pediatrics, Division of Infectious Diseases and Tropical Pediatrics, Baltimore, MD
2022 – present Assistant Professor, University of Maryland School of Medicine, Department of Pediatrics, Division of Infectious Diseases and Tropical Pediatrics, Baltimore, MD

Other Employment

2011 – 2014 On-call Physician, Pediatric Bone Marrow Transplant Unit, University of Minnesota Amplatz Children's Hospital
2012 – 2014 Attending Physician, Pediatric Emergency Room, University of Minnesota Amplatz Children's Hospital
2019 – 2022 PRN Pediatric Hospitalist, Baltimore Washington Healthcare Services, Inc., Glen Burnie, MD

Professional Society Membership

2007 – 2013 Member, American Academy of Pediatrics
2012 – present Member, American Society of Tropical Medicine and Hygiene
2013 – present Fellow, American Academy of Pediatrics
2016 – present Member, Pediatric Infectious Disease Society
2016 – 2020 Member, Infectious Disease Society of America

Honors and Awards

2006 Lora L. Marshall Scholarship, University of Wisconsin School of

2008	Medicine and Public Health, for academic achievement Lewis E. and Edith Phillips Scholarship, University of Wisconsin School of Medicine and Public Health, for academic achievement
2008	Alpha Omega Alpha (AOA) Medical Honor Society, UWSMPH AOA
2009	Dr. Elizabeth M. Smithwick Scholarship for achievement in Pediatrics, UWSMPH
2018 – 2020, 2021 – 2023	National Institutes of Health Loan Repayment Program
2019 – 2022	Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases A nationally competitive award for physician-scientists to pursue clinical research in tropical infectious diseases. One of three selected out of eleven applicants.
2019 – 2022	Pichichero Family Foundation Research Development, Vaccines for Children Initiative Award in Pediatric Infectious Diseases A nationally competitive award that supports outstanding investigators at any level in their professional career performing translational or clinical research that focuses specifically on the development of new vaccines and immunotherapeutics.
2021 – 2023	Passano Foundation Clinician-Investigator Award A joint effort between the Passano Foundation and the University of Maryland School of Medicine, this award provides support for early-stage clinician-investigators to promote the research career development of young faculty clinician investigators. Final application selected out of six applications.
2021	Winner of the 2nd E-Poster Session aka Data Blitz held during the Department of Pediatrics Virtual Research Day, May 13, 2021
2025	Department of Pediatrics Early Career Investigator Award, May 27, 2025
2025	Pediatric Infectious Diseases Society Young Investigator Award, October 20, 2025

Clinical Activities

Clinical Expertise

Board certified pediatrician

Additional board certification in the subspecialty of pediatric infectious disease

Clinical and research focus are in the areas of tropical medicine and malaria

Scope of Clinical Practice

2020 – present Pediatric Infectious Disease consult service
 ~150 patients per year
 Attending

24% FTE

Development of Clinical Programs

2012 – 2014 Assisted in the development of a Pediatric Hospital Medicine service through the University of Minnesota at a satellite hospital in a southeastern suburb of Minneapolis-St. Paul

Administrative Service

Institutional Service

2013 – 2014 Representative, Physician Informatics Committee, Fairview Ridges Hospital

2018 – present Representative, Executive Infection Control Committee, University of Maryland Medical Center

2020 – present Faculty advisor, Global Health Interest Group, University of Maryland School of Medicine

2020 – present Member, Strategic Planning Committee, Malaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine

2022 Member, Frontiers in Vaccinology Planning Committee, Center for Vaccine Development and Global Health, University of Maryland School of Medicine

2023 Lead, Frontiers in Vaccinology Planning Committee, Center for Vaccine Development and Global Health, University of Maryland School of Medicine

National Service

2018 *Ad hoc* Reviewer, *Journal of Pediatrics*

2020 *Ad hoc* Reviewer, *npj Vaccines*

2020 – 2021 Pediatric Substudy Committee co-chair, COVID-19 Community Research Partnership

2020 – 2022 Laboratory Coordinating Committee co-chair, COVID-19 Community Research Partnership

2021 – 2025 Safety Monitoring Committee member, “A Phase 1, Randomized, Placebo Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults”, sponsored by DMID, NIAID, NIH

2022 *Ad hoc* Reviewer, *Clinical Infectious Diseases*

2022 – present *Ad hoc* Reviewer, *The Journal of Infectious Diseases*

2023 *Ad hoc* Reviewer, *Open Forum Infectious Diseases*

2023 *Ad hoc* Reviewer, *Vaccine*

2023 – present	Early Career Member, Infectious Diseases Clinical Research Consortium (IDCRC), Malaria/Tropical Diseases Expert Working Group
2024	Early Career Reviewer, Vaccines against Infectious Diseases Study Section, NIH Center for Scientific Review

Teaching Service

Undergraduate/Graduate/Medical Student Teaching

2013 – 2014	Developed a pediatrics rotation for physician assistant students from Augsburg College and St. Catherine University, including curriculum development 5, 1 st through 2 nd year students – 20 contact hours/year
2014 – 2015	Co-coordinator of the Undergraduate Pediatric Rotation at University Teaching Hospital of Kigali and Rwanda Military Hospital for the National University of Rwanda, including curriculum development, teaching, evaluation, and examination 300, 2 nd through 4 th year medical students – 400 contact hours/year
2017 – 2020	Small Group Discussion Leader, Host Defense and Infectious Disease 15-20, 2 nd year medical students – 3-6 contact hours/year
2020, 2022	Lecturer, PREV 780 Molecular Epidemiology 9, graduate students – 1.5 contact hours/year
2022 – present	Lecturer, Blood and Host Defenses Topics: MMR and parvovirus; malaria 1 st year medical students – 2 contact hours/year

Resident and Fellow Teaching

2013 – 2014	Small Group Discussion Leader, Global Pediatrics Lectures in Pediatric Core Curriculum 4-8, 1 st through 4 th year residents, 4 contact hours/year
2013 – 2014	Mentor for Pediatric residents in the Global Health Track 3, 1 st year residents – 10 contact hours/year
2014 – 2015	Mentor for Pediatric residents 2, regular (no less than monthly) meetings with residents
2015 – 2016	Pediatric Global Health Noon Conference Series 20-30, 1 st through 4 th year residents – 2 contact hours/year
2020 – present	Attending Physician, Pediatric Infectious Disease Consult Service, 1 fellow, 1-2 residents, 0-1 medical students, 4-6 hours/day, 8-9 weeks per year
2024	“TORCH Infections” Approximately 15 residents, 1 contact hour
2024	“Fever in a Returned Traveler”

Approximately 15 residents, 1 contact hour

Post-Graduate Teaching

2014 – 2015 Research Mentor
1, post-graduate, 2 hours per week

Grant Support

Active Grants:

07/12/2021-07/22/2026 (PI, 75%)
“Serological markers of natural immunity to *Plasmodium falciparum* infection”
NIH NIAID 1K23AI155838 – 01A1
Project Total direct costs: \$894,553

07/10/2024-05/31/2029 (Co-Inv, 15% in Y3-4, 20% in Y5)
“Impact of early childhood malaria prevention on malaria risk at school entry (ERASE)”
NIH NIAID 1R01AI181383-01A1
Project Total Direct Costs: \$2,498,060
Responsible for leading Aim 2 to use peptide library studies to find serological responses associated with protection from *Plasmodium falciparum* infection and clinical disease after SMC and RTS,S vaccination

Pending Grants:

12/01/2025-11/30/2030 (PI, 30%)
“Effect of Malaria Vaccine Timing on Incidence and Immunogenicity”
NIH NIAID 1R01AI195542-01
Project Total Direct Costs: \$3,387,971
Submitted 2/5/2025, IRG review 6/26/2025, Score: 38, Percentile: 30%

04/01/2026 – 03/31/2031 (PI, 30%)
“Immunological Effects of Integrating Malaria Vaccination with Chemoprevention”
NIH NIAID 1R01AI198198-01
Project Total Direct Costs: \$2,331,991
Submitted 6/5/2025, Pending IRG review 10/30/2025

Completed Grants:

05/01/2006-08/15/2006	(Co-Inv, 100%, PI: F. Graziano and A. Kekitiinwa) "Relationship Between HIV-1 Subtype, Antiretroviral Response and Resistance in a Ugandan Pediatrics Clinic" Herman S. Shapiro Summer Research Award/Center for the Study of Cultural Diversity in Health Care Total Direct Costs: \$4000 Helped to design study methods; collect, analyze and interpret data; and communicate findings
01/05/2009-02/20/2009	(Co-Inv, 100%, PI: F. Graziano, K. Hansen, and D. Nansera) "Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis" KEH was supported by NIH grants, including K23 AR 050995 and R01 AG028739, FMG received grant support through NIH EY1252601, and DN received support through Fogarty International Center, U2RTW006879. Helped to collect, analyze and interpret data and communicate findings
07/01/2017-06/30/2019	(Fellow, 50%, PI: M. Levine) Fellowship training program in vaccinology NIH T32 AI007524 Annual Direct Costs: \$195,588 Led the data collection and analysis of a review of controlled human malaria infection trials at the University of Maryland; assisted with DMID 13-0088 and DMID 17-0081; developed new project ideas that led to the Burroughs-Wellcome/ASTMH and Pichichero awards
07/01/2019-04/30/2026	(PI, 5%) "In search of natural immunity: finding serologic markers of immunity after exposure to malaria" Burroughs-Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases Annual Direct Costs: \$65,000 Total Direct Costs: \$130,000
04/01/2020-08/31/2020	(Co-Inv, 25%, Site PI: K. Neuzil) "Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): A Blinded, Randomized Study" Bill & Melinda Gates Foundation/University of Washington Subaward

Project Total Direct Costs: \$432,132 (subaward)
Assisted with recruitment, screening, enrollment, assessing adverse events, and design of ancillary studies.

11/30/2018-11/29/2020 (Co-Inv, 10%; Protocol PI: M. Laurens)
“Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease Vaccine.”
Contract – private industry
PepTcell, Limited titled as SEEK
Total Direct Costs: \$721,330
Assisted with protocol and study development, recruitment, screening, enrollment, vaccination, mosquito feeds, skin biopsies, and assessing reactogenicity and adverse events

07/01/2020-02/28/2023 (Co-Inv, 5%, Site PI: W. Chen)
“Applied Research to Address the COVID-19 Emerging Public Health Emergency”
Centers for Disease Control and Prevention
75D30120C08405 contract/Vysnova Partners, Inc.
Subaward
Project Total Direct Costs: \$1,034,354 (subaward)
Assisted with protocol development, design of the pediatric ancillary study, study startup activities at UMB, participant recruitment and retention, interaction with the research management organization, co-chair of the Laboratory Coordinating Committee and Pediatric Substudy Committee

08/25/2017-08/09/2022 (Co-Inv, 5%; Protocol PI: A. Berry)
“A sub-study to evaluate epitope mapping of antibodies elicited by controlled human malaria infection, vaccination, and natural infection with Plasmodium falciparum malaria in 14-0040, 15-0052, and 13-0088”
NIH HHS 272201300022I contract, PI: Kotloff, Vaccine and Treatment Evaluation Units
Project Total direct costs: \$934,669.00
Assist with protocol development and statistical analysis plan development, and will lead the sub-study of epitope mapping for 13-0088

08/06/2014-07/31/2023 (Co-Inv, 5%; Protocol PI: M. Laurens)
“A Phase 1 Challenge Study to Evaluate Safety, Immunogenicity and Efficacy of a Malaria Vaccine (rCSP adjuvanted with GLA-LSQ), in Healthy Adults, DMID 13-0088”

NIH HHSN272201300022I contract, PI: Kotloff, Vaccine and Treatment Evaluation Units

Project Total direct costs: \$1,351,278

Assisted with protocol and study development, recruitment, screening, enrollment, vaccination, and assessing reactogenicity and adverse events

11/01/2019-10/31/2024 (PI, 5%)
“A novel, translational approach to malaria vaccine development”
Pichichero Family Foundation Vaccines for Children Initiative Research Award in Pediatric Infectious Diseases
Annual Direct Costs: \$50,000
Total Direct Costs: \$100,000

Publications

Peer-Reviewed journal articles

1. Nansera D, Graziano FM, **Friedman DJ**, Bobbs MK, Jones AN, Hansen KE. Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis. *The International Journal of Tuberculosis and Lung Disease*. 2011; 15(11): 1522-1527.
I led site initiation activities and contributed to interpretation of findings and writing and editing the manuscript.
2. **Friedman D**, Kongthavonsakul K, Oberdorfer P. Disseminated cryptococcosis in an HIV-positive boy. *BMJ Case Reports*. 2012; doi:10.1136/bcr-2012-00703
3. **Friedman-Klabanoff D**, Ball A, Rutare S, McCall N, and Blackall DP. Three Rwandan children with massive splenomegaly and Epstein-Barr virus-associated lymphoproliferative disorders: case presentations and the literature review. *J Pediatr Hematol Onc*, 2016; 38(5): e158-e161.
4. **Friedman-Klabanoff DJ**, Laurens MB, Berry AA, Travassos MA, Adams M, Strauss KA, Shrestha B, Levine MM, Edelman R, Lyke KE. The controlled human malaria infection experience at the University of Maryland. *Am J Trop Med Hyg*. 2019; 100(3): 556-565.
5. Stucke EM, Niangaly A, Berry AA, Bailey JA, Coulibaly D, Ouattara A, Lyke KE; Laurens MB, Dara A; Adams M; Pablo J, Jasinskis A, Nakajima R, Zhou AE, Agrawal S, **Friedman-Klabanoff DJ**, Takala-Harrison S, Kouriba B, Kone AK, Rowe JA, Doumbo OK, Felgner PL, Thera MA, Plowe CV, Travassos MA. Serologic responses to the PfEMP1 DBL-CIDR domain couplet are a better indicator of malaria exposure than those to the DBL- α tag. *Malar J*. 2019 Aug 13;18(1):273.
6. **Friedman-Klabanoff DJ**, Travassos MA, Ifeonu OO, Agrawal S, Ouattara A, Pike A, Bailey JA, Adams M, Coulibaly D, Lyke KE, Laurens MB, Takala-Harrison S, Kouriba B, Kone AK, Doumbo OK, Patel JJ, Thera MA, Felgner PL, Tan JC, Plowe CV, Berry AA. Epitope-specific antibody responses to a *Plasmodium falciparum* subunit

- vaccine target in a malaria-endemic population. *J Infect Dis*. 2021 Jun 4, 223(11): 1943-1947. doi: 10.1093/infdis/jiaa611. Epub 2020 Sep 29. PMID: 32992328.
7. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, Neuzil KM, Laufer MK, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang ML, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM for the **Hydroxychloroquine COVID-19 PEP Study Team**. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. *Ann Intern Med*. 2020 Mar;174(3):344-352. doi: 10.7326/M20-6519.
Assisted with recruitment, screening, enrollment, follow-up, assessment of adverse events; enrolled 19% of the participants from our site (4% of study overall) and commended for thorough and thoughtful remote adverse event assessment.
 8. **Friedman-Klabanoff DJ** and Campbell JD. A 29-day-old Infant with Poor Feeding and a Rash. *Pediatr Rev*. 2021 Jan;42(Suppl 1):S15-S18. doi: 10.1542/pir.2019-0096.
 9. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Kehtan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; **COVE Study Group**. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. PMID: 33378609.
Assisted with screening, enrollment, vaccination, follow-up, and assessment of adverse events.
 10. **Friedman-Klabanoff DJ**, Berry AA, Travassos MA, Cox C, Zhou Y, Mo AX, Nomicos EYH, Deye GA, Pasetti MF, Laurens MB. Low dose recombinant full-length circumsporozoite protein-based *Plasmodium falciparum* vaccine is well-tolerated and highly immunogenic in Phase 1 first-in-human clinical testing. *Vaccine*. 2021 Feb 22, 39(8): 1195-1200. doi: 10.1016/j.vaccine.2020.12.023. Epub 2021 Jan 22. PMID: 33494963.
 11. Peacock JE Jr, Herrington DM, Edelstein SL, Seals AL, Plumb ID, Saydah S, Lagarde WH, Runyon MS, Maguire PD, Correa A, Weintraub WS, Wierzb TF, Sanders JW; **COVID-19 Community Research Partnership Study Group**. Survey of Adherence with COVID-19 Prevention Behaviors During the 2020 Thanksgiving and Winter Holidays Among Members of the COVID-19 Community Research Partnership. *J Community Health*. 2022 Feb;47(1):71-78. doi: 10.1007/s10900-021-01021-z. Epub 2021 Aug 12. PMID: 34383157.
Assisted with study design, acted as a lead at our site for study startup activities, engaged with UMMS to recruit through MyPortfolio, assisted with participant retention activities, interacted with and completed monthly reports for the research management organization.

12. **COVID-19 Community Research Partnership Study Group.** Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership. *BMC Infect Dis.* 2021 Aug 30;21(1):889. doi: 10.1186/s12879-021-06517-6. PMID: 34461847.
Participated in the writing group for this manuscript, providing expertise regarding the serological assays used and how that could affect the analysis plan, and contributed to the writing and editing of the manuscript.
13. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; **COVE Study Group.** Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med.* 2021 Nov 4; 385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22. PMID: 34551225.
Assisted with screening, enrollment, vaccination, follow-up, and assessment of adverse events.
14. Stewart J, Krows ML, Schaafsma TT, Heller KB, Brown ER, Boonyaratanakornit J, Brown CE, Leingang H, Liou C, Bershteyn A, Schwartz MD, Agrawal V, **Friedman-Klabanoff D**, Eustace S, Stankiewicz Karita HC, Paasche-Orlow MK, Kissinger P, Hosek SG, Chu HY, Celum C, Baeten JM, Wald A, Johnston C, Barnabas RV. Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials. *JAMA Netw Open.* 2022 Feb 1;5(2):e2148325. doi: 10.1001/jamanetworkopen.2021.48325. PMID: 35157053.
Assisted with recruitment, screening, enrollment, follow-up, assessment of adverse events.
15. **Friedman-Klabanoff DJ**, Fitzpatrick MC, Deming ME, Agrawal V, Sitar S, Schaafsma T, Brown E, Neuzil KM, Barnabas RV, Laufer MK; Hydroxychloroquine COVID-19 PEP Study Team. Risk of SARS-CoV-2 acquisition is associated with individual exposure but not community-level transmission. *J Infect Dis.* 2022 Aug 24;226(2):225-235. doi: 10.1093/infdis/jiac029. PMID: 35134185.
16. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberger RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; **2019nCoV-301 Study Group.** Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *N Engl J Med.* 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub ahead of print. PMID: 34910859.
Assisted with screening, enrollment, vaccination, follow-up, and assessment of adverse events.
17. **Friedman-Klabanoff DJ**, Tjaden AH, Santacatterina M, Munawar I, Sanders JW, Herrington DM, Wierzba TF, Berry AA, COVID-19 Community Research

Partnership. Vaccine-induced seroconversion in participants in the North Carolina COVID-19 Community Research Partnership. *Vaccine*. 2022 Oct 6;40(42):6133-6140. doi: 10.1016/j.vaccine.2022.09.021. PMID: 36117003.

18. **Friedman-Klabanoff DJ**, Birkhold M, Short MT, Wilson TR, Meneses CR, Lacsina JR, Oliveira F, Kamhawi S, Valenzuela JG, Hunsberger S, Mateja A, Stoloff G, Pleguezuelos O, Memoli MJ, Laurens MB. Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial. *EBioMedicine*. 2022 Dec;86:104375. doi: 10.1016/j.ebiom.2022.104375. Epub 2022 Nov 24. PMID: 36436281.

19. **COVID-19 Community Research Partnership**. The COVID-19 Community Research Partnership: a multistate surveillance platform for characterizing the epidemiology of the SARS-CoV-2 pandemic. *Biol Methods Protoc*. 2022 Nov 28;7(1):bpac033. doi: 10.1093/biomethods/bpac033. PMID: 36589317.

Assisted with study design, functioned as a lead for the study at our site, assisted with study start-up, recruitment, and day-to-day activities, contributed to the writing and editing of the manuscript.

20. Plumb ID, Fette LM, Tjaden AH, Feldstein L, Saydah S, Ahmed A, Link-Gelles R, Wierzbica TF, Berry AA, **Friedman-Klabanoff D**, Larsen MP, Runyon MS, Ward LM, Santos RP, Ward J, Weintraub WS, Edelstein S, Uschner D. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021. *Vaccine*. 2023 Apr;41(15):2596-2604. doi: 10.1016/j.vaccine.2023.03.006. Epub 2023 Mar 9. PMID: 36932031.

Assisted with study design, functioned as a lead for the study at our site, providing expertise regarding the serological assays used and how that could affect the analysis plan, and contributed to the writing and editing of the manuscript.

21. Datar RS, Fette LM, Hinkelman AN, Hammershaimb EA, **Friedman-Klabanoff DJ**, Mongraw-Chaffin M, Weintraub WS, Ahmed N, Gibbs MA, Runyon MS, Plumb ID, Thompson W, Saydah S, Edelstein SL, Berry AA; COVID-19 Community Research Partnership. Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study. *Vaccine*. 2023 May;41(20):3204-3214. doi: 10.1016/j.vaccine.2023.03.057. Epub 2023 Mar 31. PMID: 37069033.

Provided input into the design of the vaccine hesitancy surveys, the design of the study, and the analysis plan and contributed to the writing and editing of the manuscript.

22. Berry AA, Tjaden AH, Renteria J, **Friedman-Klabanoff D**, Hinkelman AN, Gibbs MA, Ahmed A, Runyon MS, Schieffelin J, Santos RP, Oberhelman R, Bott M, Correa A, Edelstein SL, Uschner D, Wierzbica TF, for the COVID-19 Community Research Partnership. Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research Partnership. *Vaccine: X*. doi: <https://doi.org/10.1016/j.jvacx.2023.100371>. Epub ahead of print 2023 Aug 11.

Assisted in study design, functioning as a lead for the overall study at our site, providing expertise regarding the serological assays used and how that could affect the analysis plan, and contributed to the writing and editing of the manuscript.

23. **Friedman-Klabanoff DJ**, Adu-Gyasi D, Asante KP. Malaria prevention in children: an update. *Curr Opin Pediatr*. 2024 Apr 1;36(2)164-170. doi: 10.1097/MOP.0000000000001332. Epub 2023 Jan 22. PMID: 38299986.
24. **Friedman-Klabanoff DJ**, Berry AA, Travassos MA, Shriver M, Cox C, Butts J, Lundeen JS, Strauss KA, Joshi S, Shrestha B, Mo AX, Nomicos EYH, Deye GA, Regules JA, Bergmann-Leitner ES, Pasetti MF, Laurens MB. Recombinant full-length *Plasmodium falciparum* circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge. *J Infect Dis*. 2024 Jun 14;229(6):1883-1893. doi: 10.1093/infdis/jiae062. PMID: 38330357
25. Beron AJ, Yukich JO, Berry AA, Correa A, Keating J, Bott M, Wierzbica TF, Weintraub WS, **Friedman-Klabanoff DJ**, Mongraw-Chaffin M, Gibbs MA, Taylor YJ, Kissinger PJ, Hayes DV, Schieffelin JS, Burke BK, Oberhelman RA. Assessment of sociodemographic factors associated with time to self-reported COVID-19 infection among a large multi-center prospective cohort population in the southeastern United States. *PLoS One*. 2024 Sep 6;19(9):e0293787. doi: 10.1371/journal.pone.0293787. PMID: 39240796.
 Assisted in study design, functioned as a lead for the overall study at our site, and contributed to the writing and editing of the manuscript.
26. Ahmed A, DeWitt ME, Dantuluri KL, Buahin A, Castri P, **Friedman-Klabanoff D**, Gibbs M, Lagarde WH, Santos RP, Tapp H, et al. At-Home Testing to Characterize SARS-CoV-2 Seroprevalence Among Children and Adolescents. *COVID*. 2025; 5(5):68. <https://doi.org/10.3390/covid5050068>
27. **Friedman-Klabanoff DJ**, Jensen TL, Gelber CE, Pinapati RS, Tan JC, Deye GA, Regules JA, Bergmann-Leitner ES, Laurens MB, Travassos MA, Goll JB, Takala-Harrison S, and Berry AA. Vaccine-induced antibodies to a C-terminal *Plasmodium falciparum* circumsporozoite protein epitope are associated with protection. *J Infect Dis*. 2025 Aug 19;jiaf391. doi: 10.1093/infdis/jiaf391. Epub ahead of print. PMID: 40826493.
28. **Friedman-Klabanoff DJ**, Jensen TL, Lyke KE, Laurens MB, Silva JC, Stucke EM, Ouattara A, Ifeonu OO, Hodges T, Moser KA, Gelber CE, Goll JB, Hoffman SL, Patel JJ, Pinapati RS, Tan JC, Deye GA, Takala-Harrison S, Travassos MA, Berry AA. Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to *Plasmodium falciparum* peptides. *Front Immunol*. 2025 Sep 14. <https://doi.org/10.3389/fimmu.2025.1641280>. Epub ahead of print.
29. Barningham L, Carr IM, Jossi S, Cole M, Ponce A, Short M, Meneses C, Lacsina JR, Valenzuela JG, Oliveira F, Laurens MB, **Friedman-Klabanoff DJ**, Pleguezuelos O, Stead LF, and McKimmie CS. AGS-v PLUS, a Mosquito Salivary Peptide Vaccine, Modulates the Response to *Aedes* Mosquito Bites in Humans. *Vaccines*. 2025; 13(10):1026. <https://doi.org/10.3390/vaccines13101026>

Published Abstracts

1. Nansera D, Graziano F, **Friedman D**, Bobbs M, Jones A, Hansen K. Vitamin D status in Ugandan adults with HIV and tuberculosis. AIDS 2010 - XVIII International AIDS Conference: Abstract no. MOPE0122

2. **Friedman-Klabanoff DJ**, Travassos MA, Agrawal S, Ouattara A, Pike A, Bailey JA, Adams M, Coulibaly D, Lyke KE, Laurens MB, Takala-Harrison S, Kouriba B, Kone AK, Doumbo OK, Patel JJ, Thera MA, Felgner PL, Tan JC, Plowe CV and Berry AA. #63: Antibodies to Peptides Representing Plasmodium falciparum Circumsporozoite Protein Reflect Acquisition of Naturally Acquired Immunity in Malian Adults and Children. *J Pediatric Infect Dis Soc.* 2021; 10:S10-S12.

Major Invited Speeches

Local

1. **Friedman, DJ.** "Pediatric HIV in the Global Setting." Presented as part of the 2013 Global Health Course at the University of Minnesota. May 16, 2013.
2. **Friedman, DJ.** "Providing Culturally Effective Care." Grand Rounds, Fairview Ridges Hospital, August 2013.
3. **Friedman, DJ.** "Pediatric HIV in a Global Setting." Available as part of the Global Pediatrics Education Series. Recorded on November 8, 2013.
<http://www.globalpeds.umn.edu/gpeds/>
4. **Friedman, DJ.** "Learning from Our Community: Culturally Diverse Professionals Discuss Culturally Effective Care." Grand Rounds, Fairview Ridges Hospital, February 2014. Moderated a panel discussion.
5. **Friedman, DJ.** "Ending the AIDS Epidemic." Presentation for the 8th Annual Medical College of Wisconsin Global Health Fair, "Infectious Diseases: From Encounter to Containment." Milwaukee, Wisconsin. February 25, 2016.
6. **Friedman-Klabanoff, DJ.** "Pre-travel consultations." Franklin Square Grand Rounds. Baltimore, Maryland. May 7, 2024.
7. **Friedman-Klabanoff, DJ.** "Malaria Vaccines: Advancements and Future Directions." University of Wisconsin Infectious Disease Grand Rounds. Virtual. May 30, 2024.
8. **Friedman-Klabanoff, DJ.** "Malaria Vaccines: Advancements and Future Directions." Medical College of Wisconsin Infectious Disease Grand Rounds. Virtual. April 7, 2025.

Proffered Communications

National

1. **Friedman DJ**, Graziano FM, Kekitiinwa AC. "Relationship Between HIV-1 Subtype, Antiretroviral Response and Resistance in a Ugandan Pediatrics Clinic." Global Health Education Consortium Annual Conference, April 2007, Santo Domingo, Dominican Republic. POSTER.
2. Kekitiinwa A, Kasirye P, **Friedman DJ**, Coakley E, Lie Y, Graziano FM. "Examination of HIV-1 Subtype and Response to Antiretroviral (ARV) Therapy in Ugandan Children." Conference on Retroviruses and Opportunistic Infections (CROI), February 3-6, 2008. Boston, MA. POSTER.

3. Kekitiinwa A, **Friedman DJ**, Coakley E, Lie Y, Graziano FM. "Profiling Etravirine Resistance in Ugandan Children with Extended Failure of a NNRTI-inclusive Regimen as First-line ART." Conference on Retroviruses and Opportunistic Infections (CROI), February 8-11, 2009. Montreal, Canada. POSTER.
4. **Friedman-Klabanoff DJ**, Laurens MB, Berry AA, Adams M, Strauss KA, Shrestha B, Edelman R, Lyke KE. "The Controlled Human Malaria Infection Experience at the University of Maryland." 2018 Annual Conference on Vaccinology Research, April 23-25, 2018. Bethesda, Maryland. POSTER.
5. **Friedman-Klabanoff DJ**, Laurens MB, Berry AA, Travassos MA, Adams M, Strauss KA, Shrestha B, Levine MM, Edelman R, Lyke KE. "A Review of Controlled Human Malaria Infection Trials at the University of Maryland." 2018 Annual Meeting of the American Society of Tropical Medicine and Hygiene, October 30, 2018. New Orleans, Louisiana. ORAL ABSTRACT.
6. **Friedman-Klabanoff DJ**, Travassos MA, Agrawal S, Ouattara A, Pike A, Bailey JA, Adams M, Coulibaly D, Lyke KE, Laurens MB, Takala-Harrison S, Kouriba B, Kone AK, Doumbo OK, Patel JJ, Thera MA, Felgner PL, Tan JC, Plowe CV, Berry AA. "Antibodies to peptides representing *Plasmodium falciparum* circumsporozoite protein reflect acquisition of naturally acquired immunity in Malian adults and children." 2019 Annual Meeting of the American Society of Tropical Medicine and Hygiene, November 21, 2019. National Harbor, Maryland. ORAL ABSTRACT.
7. **Friedman-Klabanoff DJ**, Berry AA, Travassos MA, Cox C, Zhou Y, Kotloff KL, Mo AX, Nomicos EYH, Deye GA, Pasetti MF, Laurens MB. "Recombinant full-length circumsporozoite protein-based vaccine for *Plasmodium falciparum* is highly immunogenic at low doses in Phase 1 testing among healthy Baltimore participants." 2020 Annual Meeting of the American Society of Tropical Medicine and Hygiene, November 18, 2020. Virtual Conference due to COVID-19 pandemic. POSTER.
8. **Friedman-Klabanoff DJ**, Tjaden AH, Santacatterina M, Munawar I, Sanders JW, Herrington DM, Wierzba TF, Berry AA. "Seroconversion among adults after receiving at least one dose of a COVID-19 vaccine — COVID-19 Community Research Partnership, Mid-Atlantic, Southeast and Southern United States, December 2020-May 2021." IDWeek 2021, September 29, 2021. Virtual Conference due to COVID-19 pandemic. POSTER.
9. **Friedman-Klabanoff DJ**, Birkhold M, Short MT, Wilson TR, Lacsina JR, Oliveira F, Kamhawi S, Valenzuela JG, Hunsberger S, Mateja A, Stoloff G, Pleguezuelos O, Memoli MJ, and Laurens MB. "Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases." 2021 Annual Meeting of the American Society of Tropical Medicine and Hygiene, November 21, 2021. Virtual Conference due to COVID-19 pandemic. ORAL ABSTRACT.
10. **Friedman-Klabanoff DJ**, Jensen TL, Lyke KE, Laurens MB, Silva JC, Stucke EM, Ouattara A, Gelber CE, Goll JB, Patel JJ, Tan JC, Deye GA, Takala-Harrison S, Travassos MA, and Berry AA. "Controlled human malaria infections with NF54 and 7G8 strains elicit differential antibody responses to *Plasmodium falciparum* peptides." 2021 Annual Meeting of the American Society of Tropical Medicine and Hygiene, November 21, 2021. Virtual Conference due to COVID-19 pandemic. POSTER.

11. **Friedman-Klabanoff DJ**, Berry AA, Travassos MA, Shriver M, Cox C, Butts J, Lundeen JS, Mo AX, Nomicos EYH, Deye GA, Pasetti MF, Laurens MB. "Recombinant full-length *Plasmodium falciparum* circumsporozoite protein-based vaccine expressed in *Pseudomonas fluorescens* and adjuvanted with GLA-LSQ: results of Phase 1 testing with malaria challenge." 2022 Annual Meeting of the American Society of Tropical Medicine and Hygiene, October 31, 2022. Seattle, Washington. POSTER.
12. **Friedman-Klabanoff DJ**, Laurens MB, Coulibaly D, Thera MA, Jensen TL, Gelber CE, Goll JB, Patel JJ, Pinapati R, Tan JC, Deye GA, Richie TL, Sim BKL, Hoffman SL, Travassos MA, Takala-Harrison S, and Berry AA. "Epitope-specific differential antibody responses to *Plasmodium falciparum* circumsporozoite protein are associated with protection from malaria infection in Malian adults." 2022 Annual Meeting of the American Society of Tropical Medicine and Hygiene, November 1, 2022. Seattle, Washington. POSTER.
13. **Friedman-Klabanoff DJ**, Jensen TL, Gelber CE, Goll JB, Patel JJ, Pinapati R, Tan JC, Deye GA, Bergmann-Leitner ES, Laurens MB, Travassos MA, Takala-Harrison S, and Berry AA. "RTS,S/AS02A/1B induces antibodies to a novel *Plasmodium falciparum* circumsporozoite protein epitope with sequence similarities to the junctional region." 2023 Malaria Gordon Research Conference, Castelldefells, Spain. May 29-30, 2023. POSTER.
14. **Friedman-Klabanoff DJ**, Jensen TL, Gelber CE, Goll JB, Pinapati R, Tan JC, Deye GA, Regules JA, Bergmann-Leitner ES, Laurens MB, Travassos MA, Takala-Harrison S, and Berry AA. "Off-target antibody responses induced by RTS,S/AS02A/1B in malaria-naïve adults associated with protection against controlled human malaria infection." 2023 Annual Meeting of the American Society of Tropical Medicine and Hygiene, October 21, 2023. Chicago, Illinois. POSTER.